NEW YORK, NY / ACCESSWIRE / March 7, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH). Investors who purchased Aurinia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/auph.
The investigation concerns whether Aurinia and certain of its officers and/or directors have violated federal securities laws.
On February 28, 2022, Aurinia issued a press release announcing its financial results for the quarter and full year ended December 31, 2021. Among other items, Aurinia reported a year-over-year revenue decline and announced a lower-than-expected sales outlook for 2022. On this news, Aurinia's stock price dropped $3.94 per share, or 24.26%, to close at $12.30 on February 28, 2022.
If you are aware of any facts relating to this investigation or purchased Aurinia shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/auph. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC